Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma.

Abstract

PURPOSE:

A prospective investigation of the effect of brovincamine fumarate, a Ca2+-channel blocker, on visual field changes in normal-tension glaucoma (NTG).

METHODS:

A total of 28, age- and field-matched, patients with NTG were allocated randomly to either brovincamine fumarate (20 mg 3 times daily) or placebo (3 times daily). The patients were followed at least every 4 months for a minimum of 2.5 years, and visual field examinations were carried out at least every 6 months. The mean follow-up periods (+/-standard deviation) were 39.1 +/- 8.7 months in the brovincamine-treated group and 37.9 +/- 10.1 months in the placebo group. Stepwise discriminant analyses were performed to separate the patients who showed improvement of their visual fields from those who failed to improve in the brovincamine-treated group, and to identify factors that may determine the visual field prognosis of all patients with NTG enrolled in the study.

RESULTS:

In the brovincamine-treated group, six patients showed visual field improvement, whereas none showed improvement in the placebo group using the Statpac 2 linear regression analysis. Discriminant analyses identified better cold recovery rate and higher initial systolic blood pressure to be significantly contributory to a favorable outcome in the brovincamine-treated group, and the use of brovincamine, better cold recovery rate, and higher initial systolic blood pressure were identified to be significantly contributory to a favorable prognosis in all subjects.

CONCLUSION:

Brovincamine seems to have a favorable effect on visual field in at least some patients with NTG.

• Authors: A Sawada, Y Kitazawa, T Yamamoto, I Okabe, K Ichien
• Journal: Ophthalmology (Ophthalmology) Vol. 103 Issue 2 Pg. 283-8 (Feb 1996) ISSN: 0161-6420 [Print] United States
• PMID: 8594515 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Calcium Channel Blockers
• Vasodilator Agents
• Vincamine
• 11-bromovincamine

Topics

• Administration, Oral
• Calcium Channel Blockers (administration & dosage, therapeutic use)
• Female
• Follow-Up Studies
• Glaucoma, Open-Angle (complications, physiopathology)
• Humans
• Male
• Middle Aged
• Prospective Studies
• Vasodilator Agents (administration & dosage, therapeutic use)
• Vincamine (administration & dosage, analogs & derivatives, therapeutic use)
• Vision Disorders (etiology, physiopathology, prevention & control)
• Visual Acuity
• Visual Fields (drug effects)